Form 4: EyePoint Pharmaceuticals CEO Jay Duker Reports Stock Transactions

Jay Duker, President and CEO of EyePoint Pharmaceuticals, reports the vesting of restricted stock units and subsequent transactions involving common stock.

Summary

• On February 9, 2025, Jay Duker, the President and CEO of EyePoint Pharmaceuticals, exercised his withholding right following the vesting of restricted stock units.
• This resulted in the acquisition of 7,000 shares of common stock and the disposal of 2,055 shares to satisfy tax withholding requirements at a price of $6.495 per share.
• Following these transactions, Duker directly owns 77,651 shares of common stock and indirectly owns 22,500 shares through a family trust.
• The restricted stock units vest in three annual installments beginning February 9, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Jay Duker, EyePoint Pharmaceuticals, EYPT, Restricted Stock Units, Common Stock, Insider Trading